Predicting Outcomes following Anti-CD19 CAR T Cell Therapy in Aggressive B Cell Lymphomas

CD19-directed chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of relapsed or refractory (R/R) aggressive B cell non-Hodgkin lymphoma and has led to durable complete response (CR) rates of approximately 30% to 40% [1-4]. Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are the 2 anti-CD19 CAR T cell products currently approved by the Food and Drug Administration (FDA) for patients with R/R diffuse large B cell lymphoma (DLBCL) after receiving 2 or more previous lines of systemic therapy [1,3].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research